BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17114958)

  • 21. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
    Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
    Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
    Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2008; 47(2):293-300. PubMed ID: 18210302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
    Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
    Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
    Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
    Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Zapletalova D; André N; Deak L; Kyr M; Bajciova V; Mudry P; Dubska L; Demlova R; Pavelka Z; Zitterbart K; Skotakova J; Husek K; Martincekova A; Mazanek P; Kepak T; Doubek M; Kutnikova L; Valik D; Sterba J
    Oncology; 2012; 82(5):249-60. PubMed ID: 22538363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
    Steinbild S; Arends J; Medinger M; Häring B; Frost A; Drevs J; Unger C; Strecker R; Hennig J; Mross K
    Onkologie; 2007 Dec; 30(12):629-35. PubMed ID: 18063875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin.
    Damber JE; Vallbo C; Albertsson P; Lennernäs B; Norrby K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):354-60. PubMed ID: 16333676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
    Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
    J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.
    Briasoulis E; Pappas P; Puozzo C; Tolis C; Fountzilas G; Dafni U; Marselos M; Pavlidis N
    Clin Cancer Res; 2009 Oct; 15(20):6454-61. PubMed ID: 19808873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.
    Perroud HA; Rico MJ; Alasino CM; Queralt F; Mainetti LE; Pezzotto SM; Rozados VR; Scharovsky OG
    Future Oncol; 2013 Mar; 9(3):451-62. PubMed ID: 23469980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.